Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 1, 2026, 8:03 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 62 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Gastrointestinal Peritoneal Carcinomatosis Clear all
Completed Phase 2 Interventional Results available

Surgery and Heated Chemotherapy for Adrenocortical Carcinoma

NCT01833832
View directory record Official record
Conditions
Adrenocortical Carcinoma, Peritoneal Carcinomatosis
Interventions
Cisplatin, Cytoreductive surgery, sodium thiosulfate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Oct 1, 2026, 8:03 AM EDT
Not listed Phase 2 Interventional

Clinical Trial of Intraperitoneal Hyperthermic Chemotherapy

NCT02349958
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer, Uterine Cancer, Mesotheliomas, Gastrointestinal Cancers, Cervical Cancer
Interventions
HIPEC: MMC 30mg @ T0, 10mg @ T45min, HIPEC: MMC + CDDP 30mg @ T0, 10mg @ T45min 50 mg/m2 @T0, HIPEC: CDDP 75 mg/m2 @T0, HIPEC: CDDP+ Doxorubicin 50 mg/m2 @T0 15 mg/m2 @T0
Device
Lead sponsor
Bay Area Gynecology Oncology
Other
Eligibility
18 Years to 75 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2022
U.S. locations
1
States / cities
Los Gatos, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2019 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Cancer in the Abdomen

NCT00003046
View directory record Official record
Conditions
Anal Cancer, Colorectal Cancer, Gallbladder Cancer, Gastric Cancer, Pancreatic Cancer
Interventions
Recombinant Interleukin-12
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2001
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2012 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Trastuzumab Plus R115777 in Treating Patients With Advanced or Metastatic Cancer

NCT00005842
View directory record Official record
Conditions
Cancer
Interventions
trastuzumab, tipifarnib
Biological · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
2
States / cities
Fort Sam Houston, Texas • San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Feb 11, 2013 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Not applicable Interventional

Stress Reduction in Improving Quality of Life in Patients With Recurrent Gynecologic or Breast Cancer

NCT01764789
View directory record Official record
Conditions
Anxiety Disorder, Depression, Fatigue, Leydig Cell Tumor, Ovarian Sarcoma, Ovarian Stromal Cancer, Pain, Peritoneal Carcinomatosis, Pseudomyxoma Peritonei, Recurrent Breast Cancer, Recurrent Cervical Cancer, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Cancer, Recurrent Gestational Trophoblastic Tumor, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Cavity Cancer, Recurrent Uterine Sarcoma, Recurrent Vaginal Cancer, Recurrent Vulvar Cancer
Interventions
questionnaire administration, quality-of-life assessment, psychosocial assessment and care, behavioral intervention, cognitive intervention, educational intervention
Other · Procedure · Behavioral
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
21 Years to 85 Years · Female only
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 9, 2015 · Synced Oct 1, 2026, 8:03 AM EDT
Not listed Phase 2 Interventional

Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis

NCT03073694
View directory record Official record
Conditions
Cancer, Appendiceal, ColoRectal Cancer
Interventions
Mitomycin c, Melphalan
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 75 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Westwood, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 9, 2023 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

NCT02759588
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
Interventions
Olvi-Vec, Platinum-doublet with or without bevacizumab
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Newport Beach, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 1, 2026, 8:03 AM EDT
Terminated Phase 2 Interventional Results available

Phase 2 RCT of Alvimopan vs. Placebo After CRS/HIPEC

NCT03352414
View directory record Official record
Conditions
Ileus
Interventions
Alvimopan, Placebo
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2021 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Intraperitoneal Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Advanced Cancer of the Peritoneal Cavity

NCT00825201
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Cavity Cancer, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
paclitaxel albumin-stabilized nanoparticle formulation, liquid chromatography, mass spectrometry, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
19 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
2
States / cities
Duarte, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jan 19, 2018 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Phase 1Phase 2 Interventional

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies

NCT03834272
View directory record Official record
Conditions
Peritoneal Metastases
Interventions
LUM Imaging System
Combination Product
Lead sponsor
Lumicell, Inc.
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 16, 2026 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Phase I Trial of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Cisplatin Plus Early Postoperative Intraperitoneal Paclitaxel and 5-FU for Peritoneal Carcinomatosis

NCT00001569
View directory record Official record
Conditions
Carcinoma, Peritoneal Neoplasm
Interventions
Cisplatin, Paclitaxel, 5-FU
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Phase I Study of Continuous Hyperthermic Peritoneal Perfusion (CHPP) With Escalating Dose I.P. Platinum for Gastrointestinal Peritoneal Carcinomatosis

NCT00001332
View directory record Official record
Conditions
Peritoneal Neoplasms, Stomach Neoplasms
Interventions
CHPP with cisplatin
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 1, 2026, 8:03 AM EDT
Recruiting Not applicable Interventional

Patient Derived Vascularized MicroTumor Model of Gastrointestinal Peritoneal Carcinomatosis

NCT05844865
View directory record Official record
Conditions
Peritoneal Carcinomatosis, Gastrointestinal Peritoneal Carcinomatosis
Interventions
Biospecimen Collection (Blood, Ascites/Peritoneal Wash Fluid and/or Tumor Samples)
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 1, 2026, 8:03 AM EDT
Terminated Phase 1 Interventional

Intraperitoneal Paclitaxel-loaded TPM for Treatment of Peritoneal Carcinomatosis

NCT05159050
View directory record Official record
Conditions
Peritoneal Carcinomatosis
Interventions
Paclitaxel-loaded tumor penetrating microparticles
Drug
Lead sponsor
Carlos Chan
Other
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 1, 2026, 8:03 AM EDT
Recruiting Early Phase 1 Interventional

PhI Pilot Study Pafolacianine Inject for Intraoperative Imaging on Outcomes of GI Cancer Peritoneal Carcinomatosis

NCT06511037
View directory record Official record
Conditions
Gastrointestinal Cancer, Peritoneal Carcinomatosis
Interventions
Pafolacianine (CYTALUX) with intraoperative fluorescent near-infrared (NIR) imaging
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 1, 2026, 8:03 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Integrated Cancer Repository for Cancer Research

NCT02012699
View directory record Official record
Conditions
Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 110 Years
Enrollment
999,999 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
42
States / cities
Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Heated Mitomycin and Cisplatin During Surgery in Treating Patients With Stomach or Gastroesophageal Cancer

NCT02891447
View directory record Official record
Conditions
Gastric Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Peritoneal Carcinomatosis
Interventions
Cisplatin, Hyperthermic Intraperitoneal Chemotherapy, Mitomycin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 19, 2024 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer

NCT00310076
View directory record Official record
Conditions
Carcinoma of the Appendix, Colorectal Cancer
Interventions
thalidomide, surgery
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 23, 2018 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

Intravenous and Intraperitoneal Paclitaxel and Oral Nilotinib for Peritoneal Carcinomatosis

NCT05185947
View directory record Official record
Conditions
Gynecologic Cancer, Gynecologic Neoplasms, Peritoneal Carcinomatosis, Peritoneal Neoplasms, Ovarian Cancer, Ovarian Neoplasms, Colorectal Cancer, Colorectal Neoplasms, Appendiceal Cancer, Appendiceal Neoplasms, Cholangiocarcinoma, Breast Cancer
Interventions
Paclitaxel, Nilotinib, ECG, CT Scan CAP, Laparoscopy, Peritoneal biopsies + ascites washings
Drug · Diagnostic Test · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Phase 2 Interventional Results available

HIPEC for Peritoneal Carcinomatosis

NCT02040142
View directory record Official record
Conditions
Peritoneal Carcinomatosis, Colorectal Cancer, Appendiceal Cancer, Peritoneal Mesothelioma, Pseudomyxoma Peritonei, Gastric Cancer
Interventions
HIPEC, Mitomycin C
Procedure · Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2024
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2024 · Synced Oct 1, 2026, 8:03 AM EDT
Completed Phase 1 Interventional

Veliparib and Radiation Therapy in Treating Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis, Epithelial Ovarian, Fallopian, or Primary Peritoneal Cancer

NCT01264432
View directory record Official record
Conditions
Adult Solid Neoplasm, Peritoneal Carcinomatosis, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Laboratory Biomarker Analysis, Quality-of-Life Assessment, Radiation Therapy, Veliparib
Other · Radiation · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 21, 2017 · Synced Oct 1, 2026, 8:03 AM EDT
Withdrawn Phase 2 Interventional

Prospective Randomized Trial Evaluating Mandatory Second Look Surgery With HIPEC and CRS vs. Standard of Care in Subjects at High Risk of Developing Colorectal Peritoneal Metastases

NCT01095523
View directory record Official record
Conditions
Colorectal Carcinoma, Peritoneal Carcinomatosis
Interventions
Laparotomy+ HIPEC +/- CRS
Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 1, 2026, 8:03 AM EDT
Recruiting Phase 1 Interventional

TLR9 Immunotherapy for Peritoneal Carcinomatosis

NCT07658196
View directory record Official record
Conditions
Malignant Ascites, Colorectal Adenocarcinoma, Peritoneal (Metastatic) Cancer, Appendiceal Adenocarcinoma
Interventions
ACM-CpG
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 27, 2026 · Synced Oct 1, 2026, 8:03 AM EDT
Recruiting Phase 1 Interventional

Safety and Efficacy of PIPAC Using Single Agent Mitomycin in Solid Tumors

NCT07487168
View directory record Official record
Conditions
Peritoneal Carcinomatosis
Interventions
Mitomycin C (MMC), Pressurized Intraperitoneal Aerosolized Chemotherapy (PIPAC)
Drug · Device
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 1, 2026, 8:03 AM EDT